Thermo Fisher Scientific (TMO) – Analysts’ Weekly Ratings Changes

Thermo Fisher Scientific (NYSE: TMO) recently received a number of ratings updates from brokerages and research firms:

• 6/11/2026 – Thermo Fisher Scientific is now covered by Piper Sandler. They set a “neutral” rating and a $510.00 price target on the stock.
• 6/11/2026 – Thermo Fisher Scientific is now covered by Piper Sandler. They set a “neutral” rating and a $510.00 price target on the stock.
• 6/3/2026 – Thermo Fisher Scientific was downgraded by HSBC Holdings plc from “buy” to “hold”. They now have a $540.00 price target on the stock, down from $670.00.
• 6/3/2026 – Thermo Fisher Scientific was downgraded by HSBC Holdings plc from “buy” to “hold”. They now have a $540.00 price target on the stock, down from $670.00.
• 6/2/2026 – Thermo Fisher Scientific is now covered by Wolfe Research. They set an “outperform” rating and a $535.00 price target on the stock.
• 6/1/2026 – Thermo Fisher Scientific was upgraded by Wolfe Research to “strong-buy”.
• 5/26/2026 – Thermo Fisher Scientific had its “overweight” rating reaffirmed by KeyCorp.
• 5/14/2026 – Thermo Fisher Scientific was given a new $490.00 price target by Royal Bank Of Canada. They now have a “sector perform” rating on the stock.
• 5/14/2026 – Thermo Fisher Scientific was upgraded by Royal Bank Of Canada to “hold”.
• 5/9/2026 – Thermo Fisher Scientific was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/8/2026 – Thermo Fisher Scientific had its price target lowered by Wells Fargo & Company from $675.00 to $615.00. They now have an “overweight” rating on the stock.
• 4/27/2026 – Thermo Fisher Scientific had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $620.00 price target on the stock.
• 4/24/2026 – Thermo Fisher Scientific was upgraded by Jefferies Financial Group Inc. to “strong-buy”.
• 4/24/2026 – Thermo Fisher Scientific had its price target lowered by Stifel Nicolaus from $700.00 to $600.00. They now have a “buy” rating on the stock.
• 4/24/2026 – Thermo Fisher Scientific had its price target lowered by Robert W. Baird from $653.00 to $639.00. They now have an “outperform” rating on the stock.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.